16 recruiting, 5 not yet recruiting, 3 completed, 3 terminated. 16 Phase 2, 11 Phase 1, 4 Not applicable.
Follow MDS (Myelodysplastic Syndrome): new trials by email Literature Review of MDS (Myelodysplastic Syndrome) trials Research Report on MDS (Myelodysplastic Syndrome)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD) AlloHeme - AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome) | Enrolling by invitation | CareDx | 400 | 2026-09-24 | 2026-10-16 | |
| Dresden MDS Registry With an Accompanying Biomaterial Collection MDS (Myelodysplastic Syndrome), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome | Not yet recruiting | Technische Universität Dresden | 500 | 2026-09-01 | 2026-08-27 | |
| PRAISE-IR Versus CIBMTR Controls ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia) | Not yet recruiting | Miltenyi Biomedicine GmbH | 51 | 2026-07-31 | 2026-07-28 | |
| Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS Ivosidenib - AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome) | Phase 2 | Recruiting | Ruijin Hospital | 20 | 2026-05-22 | 2026-05-26 |
| A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients Allogeneic Hematopoietic Stem Cell Transplantation - Relapsed or Refractory Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome) | Not applicable | Recruiting | The First Affiliated Hospital of Soochow University | 30 | 2026-04-01 | 2026-04-15 |
| A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies Non interventional study - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory | Not yet recruiting | ARCE Therapeutics, Inc. | 49 | 2026-03-15 | 2025-12-08 | |
| WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment Axvitiy Ax3 accelorometer - MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia) | Recruiting | University of Oxford | 80 | 2026-02-17 | 2026-04-06 | |
| Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA Romiplostim, Recombinant Human Thrombopoietin - MDS (Myelodysplastic Syndrome), Aplastic Anemia (AA) | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 66 | 2026-01-31 | 2026-04-15 |
| Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation Treosulfan (Treo), Melphalan (Mel), Fludarabine (Flud) - AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome) | Phase 2 | Recruiting | Technische Universität Dresden | 220 | 2026-01-21 | 2026-09-02 |
| Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation RIC regimen - AML (Acute Myeloid Leukemia), MDS/AML | Phase 2 | Not yet recruiting | University Hospital Tuebingen | 27 | 2026-01-01 | 2025-10-09 |
| Luspatercept + Darbepoetin in MDS Luspatercept, Darbeopoetin - MDS (Myelodysplastic Syndrome) | Phase 2 | Recruiting | Yale University | 60 | 2025-12-16 | 2026-09-14 |
| Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation Sulforaphane - ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 36 | 2025-10-22 | 2025-12-30 |
| Haplo-Cord HSCT for AML/MDS haplo-cord HSCT, Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX) - MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia) | Not applicable | Recruiting | Fujian Medical University Union Hospital | 82 | 2025-10-20 | 2026-06-10 |
| PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS PBSS1113 - Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome) | Phase 1 / Phase 2 | Recruiting | Chaser Therapeutics, Inc. | 29 | 2025-09-08 | 2026-08-14 |
| A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C - AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL) | Phase 2 | Recruiting | Center for International Blood and Marrow Transplant Research | 358 | 2025-07-25 | 2026-03-17 |
| Romiplostim N01 for Platelet Recovery After Haploidentical HSCT Romiplostim N01, Standard Supportive Care - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome) | Phase 1 | Recruiting | First Affiliated Hospital of Zhejiang University | 130 | 2025-06-01 | 2026-01-28 |
| Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS ARD103, Cyclophosphamide, Fludarabine - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Recruiting | ARCE Therapeutics, Inc. | 49 | 2025-05-20 | 2025-12-10 |
| A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT Azacitidine (AZA) Days 1 - 5, Selinexor - Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome) | Phase 1 / Phase 2 | Active not recruiting | Liping Dou | 58 | 2025-05-01 | 2026-08-21 |
| A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies CG009301 for Injection - Leukemia, AML | Phase 1 | Recruiting | Cullgen (Shanghai),Inc | 45 | 2025-04-17 | 2026-01-16 |
Showing 20 of 30. Sign in to see all of them.
Anemia, Refractory, with Excess of Blasts (30) · Leukemia, Myeloid, Acute (23) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia (5) · Leukemia, B-Cell (4) · Lymphoma, Non-Hodgkin (4) · Myelodysplastic Syndromes (4) · Hodgkin Disease (3) · Leukemia, Biphenotypic, Acute (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma (3) · Myeloproliferative Disorders (3) · Anemia, Aplastic (2) · Hematologic Diseases (2)
Anemia (30) · Anemia, Refractory (30) · Bone Marrow Diseases (30) · Hemic and Lymphatic Diseases (30) · Hematologic Diseases (28) · Myelodysplastic Syndromes (26) · Neoplasms (24) · Neoplasms by Histologic Type (24) · Leukemia, Myeloid (23) · Leukemia (19) · Disease Attributes (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoproliferative Disorders (8)
Cyclophosphamide (3) · Melphalan (3) · fludarabine (3) · Antilymphocyte Serum (1) · Azacitidine (1) · Bone Marrow Transplantation (1) · Busulfan (1) · Clinical Trials, Phase I as Topic (1) · Cytarabine (1) · Filgrastim (1) · Honey (1) · Injections (1) · Mesna (1) · Mycophenolic Acid (1) · Stem Cell Transplantation (1)
National Heart, Lung, and Blood Institute (NHLBI) (4) · ARCE Therapeutics, Inc. (2) · Ossium Health, Inc. (2) · Technische Universität Dresden (2) · The First Affiliated Hospital of Soochow University (2) · CareDx (1) · Center for International Blood and Marrow Transplant Research (1) · Chaser Therapeutics, Inc. (1) · Children's Hospital of Philadelphia (1) · Cullgen (Shanghai),Inc (1) · First Affiliated Hospital of Zhejiang University (1) · Fondazione Italiana Sindromi Mielodisplastiche-ETS (1) · Fujian Medical University Union Hospital (1) · Incyte Corporation (1) · Institute of Hematology & Blood Diseases Hospital, China (1)
United States (14) · China (9) · Germany (3) · Italy (2) · United Kingdom (1)
Minocher M Battiwalla, M.D. (2) · Antonella Poloni, MD (1) · Christoph Faul, Dr. (1) · Depei Wu (1) · Emanuele Angelucci, MD (1) · Enrico Balleari, MD (1) · Esther Oliva, MD (1) · Fang Dong (1) · Federica Pilo, MD (1) · Francesco Passamonti, MD (1) · Gastone Castellani, Physics (1) · Jianxiang Wang, MS (1) · Lorenza Borin, MD (1) · Matteo Della Porta, MD (1)
PMID 10861324, PMID 18997171, PMID 19117511, PMID 19230772, PMID 21684344, PMID 22133778, PMID 22740453, PMID 23524640, PMID 24136165, PMID 24558201, PMID 24656536, PMID 24782322, PMID 25426837, PMID 25891003, PMID 26450984, PMID 26551633, PMID 26667601, PMID 26858277, PMID 27518663, PMID 27601546, PMID 27602666, PMID 28092685, PMID 28436973, PMID 28665419, PMID 28836267, PMID 28913963, PMID 28913966, PMID 29159410, PMID 29860482, PMID 30304655, PMID 30372796, PMID 31270102, PMID 31431695, PMID 31477550, PMID 31739455, PMID 32247396, PMID 32518291, PMID 33832208, PMID 34455741, PMID 34804017
2025 (1), P01CA049605 (1)